A peptide vaccine extended survival in an aggressive leukemia in a phase 3 trial
people (phase 3 trial)
SELLAS Life Sciences says galinpepimut-S, a peptide vaccine against the WT1 protein, gave AML patients in second remission a median of 24.0 months of survival versus 14.7 on best available treatment.
What happened
On November 17, 2026, SELLAS Life Sciences announced topline results from REGAL, its pivotal phase 3 trial of galinpepimut-S, or GPS. GPS is an immunotherapeutic cancer vaccine made of peptides from WT1, a protein that many leukemia cells carry.
The trial met its main goal, overall survival. The results come from the company's press release and have not yet been published in a peer-reviewed journal.
Who was in the trial
REGAL enrolled 126 people with acute myeloid leukemia (AML) who had reached a second or later complete remission after salvage therapy and could not have, or were not able to undergo, a stem cell transplant. This is a group with few options: the leukemia has already come back at least once.
Patients were randomized one to one. Half got GPS alone as maintenance. The other half got their doctor's choice of best available treatment: watching and waiting, a hypomethylating agent, venetoclax, and/or low-dose cytarabine.
The numbers
Median overall survival was 24.0 months on GPS and 14.7 months on best available treatment. The hazard ratio was 0.59, which the company describes as a 41% lower risk of death, with a p-value of 0.035.
The few patients who went on to a stem cell transplant were split evenly between the two groups, so transplants do not explain the difference.
What comes next
SELLAS plans to meet the US Food and Drug Administration to discuss an accelerated filing strategy, and is preparing a Biologics License Application for GPS in the first half of 2027.
GPS is a cancer treatment given in a clinic. It is a different kind of peptide from the ones people run for recovery or weight loss, but it is one more sign that peptides are moving into late-stage medicine.
The numbers
- Phase 3 REGAL, 126 patients with AML in second or later remission
- Median overall survival 24.0 months on GPS vs 14.7 on best available treatment
- Hazard ratio 0.59 (41% lower risk of death), p=0.035
- BLA submission planned for the first half of 2027
- Topline results from a company press release, not yet peer-reviewed
The original: SELLAS Life Sciences press release